Regulation of laboratory-developed tests and in-house in vitro diagnostic medical devices in the United States and the European Union-a comparative overview [0.03%]
A Kahles,A-L Volckmar,H Goldschmid et al.
A Kahles et al.
Process chains in medical diagnostic laboratories lead to an accurate diagnosis and consequently to optimized personalized therapy recommendations. In addition to approved commercial in vitro diagnostic medical devices, devices and tests ma...
Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board [0.03%]
全外显子组测序在分子肿瘤委员会中的临床效益分析：一项真实世界研究
E Krieghoff-Henning,T Michaeli,T Boch et al.
E Krieghoff-Henning et al.
Background: Panel sequencing, whole-exome sequencing (WES) and whole-genome sequencing (WGS) often uncover therapeutic targets for cancer patients. However, it is still largely unclear to what extent patients directly ben...
Safety and efficacy of tiragolumab, atezolizumab and chemotherapy for early-stage or PD-L1-positive advanced triple-negative breast cancer: a phase Ib study [0.03%]
针对早期或PD-L1阳性晚期三阴性乳腺癌患者使用tiragolumab、atezolizumab和化疗的疗效与安全性：一项Ⅰb期研究
S Kuemmel,K H Jung,L Andrade et al.
S Kuemmel et al.
Background: Immune checkpoint inhibitors have transformed the management of triple-negative breast cancer (TNBC) but outcomes could be improved further. We explored combining the T-cell immunoreceptor with immunoglobulin ...
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohort [0.03%]
PROMENADE： Pembrolizumab治疗早期ER低表达/HER2阴性乳腺癌的法国真实世界队列研究
F Cherifi,L Cabel,C Bousrih et al.
F Cherifi et al.
Background: In the phase III KEYNOTE-522 study (NCT03036488), which defined triple-negative breast cancers (TNBCs) as tumours with an estrogen receptor (ER) level ≤1% (ER-null) according to European Society for Medical O...
Laboratory Prognostic Index (LAB-PI) in diffuse large B-cell lymphoma: a single blood analysis predicts outcomes as good as IPI, NCCN-IPI, and GELTAMO-IPI [0.03%]
DLBCL实验室预后指数(LAB-PI):单次血液分析的预后价值与IPI、NCCN-IPI和GELTAMO-IPI相当
F Martin-Moro,L Bento,J Marquet et al.
F Martin-Moro et al.
Background: Many prognostic variables have been described in diffuse large B-cell lymphoma (DLBCL) and combined in prognostic scores, which are not usually fully objective and may be complex to apply. With the aim of desi...
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancer [0.03%]
乳腺癌治疗前的RNA表达特征和反复出现的基因组改变的综合分析：与绝经状态，短期内分泌治疗反应和无病生存期之间的联系在 Luminal 乳腺癌中的作用
G Zhang,H Ni,L Mishieva et al.
G Zhang et al.
Background: Endocrine therapy with tamoxifen (TAM) or aromatase inhibitors (AI) is an effective treatment of patients with estrogen receptor-positive, HER2-negative luminal breast cancer. However, many patients do not res...
Impact of the Lung Immune Prognostic Index in non-small-cell lung cancer patients with PD-L1-low/negative tumors receiving chemoimmunotherapy: a real-world multicenter retrospective study [0.03%]
程序性死亡配体1低表达/阴性的非小细胞肺癌患者接受化疗联合免疫治疗的肺免疫预后指数影响：一项真实世界多中心回顾性研究
A Yoshimura,T Takeda,K Tanimura et al.
A Yoshimura et al.
Background: Chemoimmunotherapy has become one of the standard first-line treatment options for advanced non-small-cell lung cancer (NSCLC) across programmed death-ligand 1 (PD-L1) strata, yet outcomes in PD-L1-low/negativ...
Bevacizumab plus chemotherapy versus chemotherapy in untreated advanced non-squamous non-small-cell lung cancer patients with brain metastases (BAP BRAIN): an open-label, randomized, multicenter, phase III study [0.03%]
贝伐单抗联合化疗对比单纯化疗用于未经治疗的伴脑转移非鳞状非小细胞肺癌患者的III期开放多中心随机临床试验（BAP BRAIN）
M Li,Y Pan,G Jiang et al.
M Li et al.
Background: There is a lack of prospective randomized controlled trials of antiangiogenic therapy in patients with brain metastases. We conducted this phase III, randomized, multicenter study (BAP BRAIN) to evaluate the i...
First-in-human study of a thorium-227-labeled mesothelin-targeting antibody-chelator conjugate (MSLN-TTC), in patients with malignant mesothelioma and other solid tumors [0.03%]
一种 targeting MSLN的抗体缀合物(MSLN-TTC)在恶性间皮瘤和其他实体肿瘤患者中的首次人体研究
A Minchom,O Lindén,D G Knapen et al.
A Minchom et al.
Introduction: BAY 2287411 [227Th-anetumab corixetan; mesothelin-targeting antibody-chelator conjugate (MSLN-TTC)] is a targeted alpha therapy consisting of a fully human mesothelin-targeting monoclonal antibody conjugated...